Skip to main content

Table 3 Hepatitis B acquisition and future burden estimates for infants born in government maternity hospitals with current vaccination programming with the DPT series in Kabul, Afghanistan.

From: Seroprevalence and correlates of HIV, syphilis, and hepatitis B and C virus among intrapartum patients in Kabul, Afghanistan

 

Number Without Program

Number With Program

Number Prevented

Percent Reduction

A. Disease Events Prevented (Future burden)

Total HBV infections

27,054

19,735

7,319

27%

Acute symptomatic hepatitis B cases

5,400

3,933

1,467

27%

Chronic HBV infections

4,937

3,625

1,313

27%

HBV-related deaths:

    

Acute hepatitis B

23

17

6

27%

Cirrhosis

268

197

71

27%

Hepatocellular carcinoma

170

125

45

27%

   Total Deaths

460

338

123

27%

B. Number of Infections by Age at Acquisition of Infection (Future burden)

Perinatal Infection

117

117

0

0%

Early Childhood Infection

13,410

9,766

3,643

27%

Late Infection

13,527

9,852

3,675

27%

Total Infections

27,054

19,735

7,319

27%

C. Number of Chronic Infections by Age at Acquisition of Infection (Future burden)

Perinatal Infection

106

106

0

0%

Early Childhood Infection

4,021

2,929

1,093

27%

Late Infection

811

590

220

27%

Total Infections

4,937

3,625

1,313

27%

D. Number of Deaths by Age at Acquisition of Infection (Future burden)

Perinatal Infection

9

9

0

0%

Early Childhood Infection

362

264

98

27%

Late Infection

89

65

24

27%

Total Deaths

460

338

123

27%

   Appendix. Input values

    

Prevalance HBsAg among women of child bearing age:

1.3

Prevalence HBeAg among HBsAg-positive women of child bearing age:

12.5

Prevalence of any marker of HBV infection among 5 year olds:

30

Prevalence of any marker of HBV infection among 30+ year olds:

60

Estimated Hepatitis B3 coverage:

28.6

Estimated coverage with birth dose hepatitis B vaccine:

0